Utah Retirement Systems Has $32.95 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Utah Retirement Systems increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,342 shares of the medical research company’s stock after acquiring an additional 100 shares during the period. Utah Retirement Systems’ holdings in Thermo Fisher Scientific were worth $32,952,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in TMO. Barrett & Company Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth about $28,000. FPC Investment Advisory Inc. bought a new stake in Thermo Fisher Scientific in the 4th quarter worth about $28,000. Missouri Trust & Investment Co bought a new stake in Thermo Fisher Scientific in the 4th quarter worth about $29,000. Pillar Financial Advisors LLC bought a new stake in Thermo Fisher Scientific in the 4th quarter worth about $29,000. Finally, Endeavor Private Wealth Inc. bought a new stake in Thermo Fisher Scientific in the 4th quarter worth about $30,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on TMO shares. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Wednesday, April 23rd. Evercore ISI reduced their target price on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target on the stock in a research note on Friday, January 10th. Morgan Stanley upped their price target on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Finally, Stifel Nicolaus dropped their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Five equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $610.27.

Thermo Fisher Scientific Price Performance

TMO opened at $427.56 on Wednesday. The stock has a 50-day moving average price of $482.87 and a 200-day moving average price of $524.80. Thermo Fisher Scientific Inc. has a 12-month low of $409.85 and a 12-month high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $161.40 billion, a P/E ratio of 25.87, a PEG ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Thermo Fisher Scientific’s quarterly revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the business posted $5.11 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.40%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares of the company’s stock, valued at $59,506,950.58. This represents a 7.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the transaction, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at $9,582,009.17. The trade was a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock worth $13,106,062 in the last ninety days. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.